U.S., April 8 -- ClinicalTrials.gov registry received information related to the study (NCT07515404) titled 'A New Multimodal and Semi-specific Therapeutic Plasmapheresis Concept, a Case Series Study' on March 31.
Brief Summary: Global demand for therapeutic plasmapheresis is rising to treat various immunological, rheological, and lipoprotein-related disorders. Traditional therapeutic plasma exchange (TPE) removes plasma entirely and replaces it with costly substitution fluids, making it less sustainable. Semi-specific methods like plasma adsorption and double-filtration plasmapheresis (DFPP) avoid this by purifying and reinfusing the patient's own plasma.
DFPP, although effective and widely reimbursed in Europe and Asia, relies on membra...